Latif Nasser

They write an op-ed in the Times that basically says, look, this is crazy, $11,000 a month for a drug that maybe gives you 42 more days of life?

Is that worth it?

And a little less than a month after the op-ed piece came out,

The company that makes Altrap.

They went to individual doctor's offices, sent representatives and said, we are offering a 50% discount.

They cut the price in half just like that?

Yep.

Nationwide or like just in this area?

Nationwide.

It was sort of incredible.

We reached out to Sanofi to talk about the price of Zaltrap and they declined to comment.

But in a statement that they released when this whole Zaltrap thing happened, they said that they incur so many costs for researching and developing and bringing a drug to market that that is what their pricing is based on.

Leonard doesn't disagree.

We need these companies.

They're the ones developing the drugs.

Which aren't easy to develop.

I mean, Leonard gave us just one example.

If we talk about colon cancer.

He says for years, there was only one drug on the market called 5-FU.

5-FU was patented in August of 1957.